Mark Pruzanski, Intercept CEO (GlobeNewswire via YouTube)
September 1, 2020 05:14 PM EDT
Pharma

Spurned by the FDA, In­ter­cept brings out the bud­get axe and chops 170 jobs

John Carroll

Editor & Founder

The un­ex­pect­ed CRL that land­ed at In­ter­cept Phar­ma­ceu­ti­cals $ICPT 2 months ago is cost­ing the biotech dear­ly.

In an SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

A service from the Financial Times